Community Acquired Bacterial Pneumonia Treatment Market to Hit US$ 2672.1 million by 2030: Growth Plus Reports

Newark, New Castle, USA, March 23, 2023 (GLOBE NEWSWIRE) — According to the deep-dive market assessment study by Growth Plus Reports, the global community acquired bacterial pneumonia treatment market was valued at US$ 1,503.3 million in 2021 and is expected to register a revenue CAGR of 6.6% to reach US$ 2672.1 million by 2030.

Market Drivers

The growing number of geriatric population is the primary driver for the growth of global community acquired bacterial pneumonia treatment. For instance, according to the WHO’s October 2022 factsheet, all countries are facing the major challenge of a rising geriatric population, and its rising at a much faster pace than in the past. The factsheet also includes, by 2030, 1 in 6 people will be aged 60 or above. Given the emergence of antibiotic-resistant bacteria, the discovery of novel medicines that are effective against these diseases is critical. This has resulted in an increase in antibacterial medication research & development, which is projected to boost the growth of the community acquired bacterial pneumonia treatment market. Many governmental organizations throughout the world are investing in research & development operations to produce new antibiotics, as well as measures to encourage effective community acquired bacterial pneumonia treatment diagnosis and treatment. These activities and financing are likely to propel the growth of the global community acquired bacterial pneumonia treatment market. The rise in healthcare expenditure throughout the world is likely to make community acquired bacterial pneumonia therapy more affordable, fueling the growth of the community acquired bacterial pneumonia treatment market.

The global community acquired bacterial pneumonia treatment type market is analyzed from four perspectives: Treatment Type, Route of Administration, Distribution Channel, and Region.

Request a Free Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/community-acquired-bacterial-pneumonia-treatment-market/8290

Community Acquired Bacterial Pneumonia Treatment Market Scope

Excerpts from ‘By Treatment Type Segmentation’

Based on the treatment type, the global community acquired bacterial pneumonia treatment market is segmented into:

• Antibiotics
• Antivirals
• Others

The antibiotics segment dominated the market with the principal revenue share in 2021, owing to the availability of a wide range of antibiotics, advancements in antibiotic development, and government initiatives. Antibiotics are the most commonly used treatment for community acquired bacterial pneumonia and are recommended as the first line of treatment by medical guidelines. The availability of a diverse spectrum of antibiotics has expanded the treatment choices available to healthcare practitioners for community-acquired bacterial pneumonia. Many governmental efforts across different regions have been developed to boost antibiotic development and prevent antibiotic resistance. These initiatives have raised investment in antibiotic research and development, propelling the antibiotics segment of the community acquired bacterial pneumonia treatment market forward.

Excerpts from ‘By Route of Administration Segmentation’

Based on the route of administration, the global community acquired bacterial pneumonia treatment market is bifurcated into:

The oral route segment dominated the market with the largest revenue share in 2021, attributed to patient preference, availability of effective oral antibiotics, and reduced risk of complications. For the treatment of community-acquired bacterial pneumonia, various antibiotic classes are available, including macrolides, fluoroquinolones, penicillin’s, cephalosporins, and others. The availability of a diverse spectrum of antibiotics has expanded the treatment choices available to healthcare practitioners for community-acquired bacterial pneumonia. Many government efforts have been developed to boost antibiotic development and prevent antibiotic resistance. These initiatives have raised investment in antibiotic research and development, propelling the antibiotics section of the community acquired bacterial pneumonia treatment market forward.

Excerpts from ‘By Region Segmentation’

Based on the global community acquired bacterial pneumonia treatment market has been segmented into:

• North America
• Europe
• Asia Pacific
• Rest of the World

North America was leading the global community acquired bacterial pneumonia treatment market in 2021, owing to rising research & development activities, rising healthcare expenditure, and the presence of major players. Companies across this region are consistently involved in research & development activities for launching new and novel medication for the treatment of community acquired bacterial pneumonia. For instance, in December 2022, Clarametyx Biosciences launched Phase Ia bacterial pneumonia antibody trial. The trial will analyze the safety of up to four doses of the antibody in healthy subjects. On concluding the Phase Ia portion of the trial, the company will commence the placebo-controlled, double-blind, randomized Phase Ib segment. The trial launch is backed by various preclinical studies where CMTX-101 showed anti-biofilm activity. A new antibody, CMTX-101 is created for treating serious bacterial infections. It quickly eliminates the bacterial biofilms’ universal underlying structure to subsequently weaken extracellular bacterial defences and facilitate efficient antibiotic and immune intervention.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/community-acquired-bacterial-pneumonia-treatment-market/8290

Excerpts from ‘Competitive Landscape’

Some prominent players operating in the global community acquired bacterial pneumonia treatment market are:

• Nabriva Therapeutics plc
• Cumberland Pharmaceuticals Inc.
• Paratek Pharmaceuticals, Inc.
• Eagle Pharmaceutical Inc.
• Pfizer Inc.
• Eli Lilly & Company
• GSK plc
• Forest Pharmaceuticals
• Sanofi S.A.
• Teva Pharmaceuticals Industries Limited
• Merck Sharp & Dohme Inc.
• Cubist Pharmaceuticals LLC
• Shionogi Inc.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecast Years – 2022 to 2030
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2021) 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL COMMUNITY ACQUIRED BACTERIAL PNEUMONIA TREATMENT MARKET – ANALYSIS & FORECAST, BY TREATMENT TYPE
   1. Antibiotics
   2. Antivirals
   3. Others
6. GLOBAL COMMUNITY ACQUIRED BACTERIAL PNEUMONIA TREATMENT MARKET – ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
   1. Oral
   2. Intravenous
7. GLOBAL COMMUNITY ACQUIRED BACTERIAL PNEUMONIA TREATMENT MARKET – ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL 
   1. Hospitals Pharmacy
   2. Retail Pharmacy
   3. Online Pharmacy

TOC Continued..

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8290

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse related reports:

Anti-Inflammatory Peptides Market by Application (Gastrointestinal Diseases, Neurological Diseases, Cardiovascular Diseases), Distribution Channel (Hospital Pharmacy, Retail Pharmacy)-Global Outlook & Forecast 2022-2030

Medical Tape Market by Material (Paper Tape, Fabric Tape, Plastic Tape), Application (Wound Care, IV Set Placement), End User (Hospitals, Clinics, Ambulatory Centers) – Global Outlook & Forecast 2022-2030

Nurse Call Systems Market by Technology (Wireless and Wired), Product (Basic Button Based Systems, Mobile Integrated Systems, IP Based Systems), End-user (Hospitals & Clinics, Nursing Centers, Home Care Settings) – Global Outlook & Forecast 2022-2030

Orthopedic Power Tools Market by Product Type (Instruments, Accessories), Technology (Electric, Pneumatic, Battery), Usage (Reusable, Disposable), End-User (Hospitals, Ambulatory Centers, Specialty Clinics) – Global Outlook & Forecast 2022-2030

Intraocular Lens Market by Type (Monofocal, Multifocal, Toric, Accommodative), Material (Acrylic, Silicone, Polymethyl Methacrylate), End User (Hospitals & Clinics, Eye Research Institutes, Ambulatory Centers) – Global Outlook & Forecast 2022-2030

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.